A proteomic signature that reflects pancreatic beta-cell function.

Area of Science:

• Endocrinology
• Metabolomics
• Proteomics

Background:

• Pancreatic beta-cell dysfunction is central to type 2 diabetes development.
• Current assessment via oral glucose tolerance tests (OGTT) is time-consuming and burdensome.
• Proteomics offers a potential avenue for early identification and monitoring of beta-cell dysfunction.

Purpose of the Study:

• To identify protein signatures and pathways associated with pancreatic beta-cell function using fasting blood samples.
• To establish a more efficient method for assessing beta-cell function compared to OGTT.
• To explore the role of specific proteins in modulating insulin secretion.

Main Methods:

• Proteomic analysis of 1,129 proteins in 100 participants from the MECHE study.
• Calculation of beta-cell function measures (HOMA-IR, disposition index) from OGTT data.
• Statistical analysis including receiver operating characteristic (ROC) curves and linear regression.
• In vitro validation using the BRIN-BD11 pancreatic beta-cell line.

Main Results:

• Twenty-two proteins significantly associated with beta-cell function/HOMA-IR and 17 with the disposition index (p ≤ 0.01).
• Protein panels demonstrated excellent discrimination between low and high beta-cell function via ROC analysis.
• Beta-endorphin and IL-17F strongly associated with beta-cell function/HOMA-IR; Calcineurin and CRTAM with disposition index.
• In vitro studies confirmed IL-17F modulates insulin secretion, increasing glucose-stimulated insulin secretion at 10 ng/mL.

Conclusions:

• Proteomic profiling of fasting blood can identify key proteins linked to beta-cell function.
• Specific proteins like IL-17F show potential as biomarkers for beta-cell dysfunction.
• Early detection through proteomics may enable timely interventions to prevent type 2 diabetes progression.